PTC Therapeutics (PTCT) said Monday that a phase 2 study of PTC518, or votoplam, in stage 2 and 3 Huntington's disease met its primary endpoint of reduction in blood Huntingtin protein levels at week 12.
The company said the study showed dose-dependent lowering of blood Huntingtin levels, with 23% at the 5mg dose for both stage 2 and stage 3 patients. Treatment may differ at the 10mg dose level based on the study results, according to the company.
Votoplam also demonstrated a favorable safety and tolerability profile across all dose levels and disease stages, PTC Therapeutics added.
Shares of PTC Therapeutics were down nearly 16% in recent premarket activity Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。